Since CD20 antibodies are frequently included in current treatment regimens employing the small molecule inhibitors, we excluded that rituximab did influence the effect of BAFF on treatment susceptibility of the CLL cells (Figure 1B). The gene discussed is TNFSF13B; the disease is B-cell chronic lymphocytic leukemia.